business / news / / Business Today
Sun Pharmaceutical Industries Ltd shares are trading flat on Tuesday.
Sun Pharma will acquire Organon in an all-cash deal, valuing Organon at $11.75 billion enterprise value.
KEY POINTS
- The acquisition will transition Sun Pharma from a net cash to a net debt company with about $8 billion debt.
- HDFC Securities expects the deal to be EBITDA accretive by 82% in FY28 for Sun Pharma.
- The Organon deal gives Sun Pharma immediate access to a $691 million biosimilar business and Chinese market strength.
- Post-acquisition, Organon will be delisted from the New York Stock Exchange, likely in early 2027.
COMPANIES
Summarized by Newsio from Business Today. How we summarize →